규제 업데이트
2026년 9월 5일•1분 읽기
FDA Approves NDA007392 for Secobarbital Sodium Injection (Seconal)
FDA has approved NDA007392 for Seconal Sodium injectable, a secobarbital sodium product by Lilly, with a detailed submission history and discontinued marketing status.
1
규제 업데이트
2026년 8월 30일•1분 읽기
FDA Approves Lilly Methyltestosterone Tablet ANDA080256 (Discontinued)
FDA approved Lilly's ANDA080256 for methyltestosterone tablets (10 mg and 25 mg) buccal/sublingual on Dec 22 1971; both products are now discontinued.